Related Experiment Videos
[Antibiotic therapy in bronchopulmonary infections]
M Moroni1, F Franzetti, S Antinori
1Clinica delle Malattie Infettive, Università degli Studi di Milano.
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna
|July 1, 1992
Summary
Treatment for respiratory infections is challenging due to diagnostic difficulties. Streptococcus pneumoniae is a common pneumonia cause, with specific treatments for atypical pneumonia and bronchitis based on patient factors and local resistance.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Context:
- Lower respiratory tract infections (LRTI) present diagnostic challenges, complicating ideal treatment selection.
- Empirical treatment relies on clinical and epidemiological data, with Streptococcus pneumoniae being a primary pathogen.
- Emerging pathogens like Chlamydia pneumoniae and Moraxella catarrhalis influence treatment strategies.
Purpose:
- To review current understanding and suggested treatment regimens for various lower respiratory tract infections.
- To highlight pathogen-specific and patient-specific approaches to antibiotic therapy.
- To discuss management strategies for nosocomial pneumonia and infections in immunocompromised hosts.
Summary:
- Streptococcus pneumoniae is the most frequent cause of pneumonia; macrolides are recommended for atypical pneumonia in younger patients.
- Older adults may be treated with amoxycillin-ampicillin, cephalosporins, or cotrimoxazole, depending on susceptibility.
- Nosocomial pneumonia requires coverage for Gram-negative bacilli, with newer monotherapies showing promise.
- Management of pneumonia in immunocompromised patients hinges on host defect and radiographic patterns.
Impact:
- Provides guidance for optimizing antibiotic selection in diverse respiratory infection scenarios.
- Emphasizes the importance of pathogen identification and local resistance patterns in treatment decisions.
- Informs clinical practice for both community-acquired and hospital-acquired pneumonia, including complex cases in immunocompromised individuals.